Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Connect Biopharma Holdings Limited (Nasdaq: CNTB), a biopharmaceutical firm focused on T cell-driven therapies for inflammatory diseases, announced its participation in several upcoming investor and scientific conferences. Key events include the 6th Annual Dermatology Drug Development Summit in Boston (Nov 1-3), where CEO Zheng Wei will present on Nov 2, and others through December, including the Piper Sandler Healthcare Conference in New York. The company continues to develop promising therapies, including its lead candidate targeting IL-4Rα for atopic dermatitis.
Details
News Market Reaction – CNTB
The recorded move for CNTB in the trading session of this news was +0.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences:
- 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Boston, November 1-3; Connect CEO Zheng Wei will present “Spearheading a Novel Compound Targeting the IL-4Rα Cytokine Receptor in Atopic Dermatitis,” on Wednesday, Nov. 2 at 12:00pm EDT. Additional information can be found at: https://dermatology-drugdevelopment.com/
- BioCentury-Bay Helix East West Conference, Redwood City, Calif., November 14 - 18
- Piper Sandler 34th Annual Healthcare Conference, New York, Nov. 29 - December 1
- Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference, Miami, December 8
For more information on presentation dates and times, please visit Connect Biopharma’s website under investor presentations: https://investors.connectbiopharm.com/presentations-events/events or to schedule a one-on-one meeting with management, send an email to: IR@Connectpharm.com.
About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/
INVESTOR CONTACT:
Ina McGuinness
805.427.1372
imcguinness@connectpharm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.